Cefepime Shortage: A Provider Briefing for 2026

The intermittent shortage of Cefepime injection continues to create challenges for hospitals, outpatient infusion centers, and prescribers managing serious bacterial infections. As a fourth-generation cephalosporin with broad gram-negative and gram-positive activity — including anti-Pseudomonal coverage — Cefepime occupies a critical role in empiric and directed therapy for pneumonia, complicated UTIs, intra-abdominal infections, and febrile neutropenia.

This briefing provides prescribers with an updated overview of the shortage timeline, clinical implications, alternative therapy options, cost considerations, and practical tools to support patient access.

Shortage Timeline

Cefepime injection has been subject to intermittent shortages since approximately 2010. Key milestones include:

• 2010–2015: Multiple periods of limited availability driven by manufacturing quality issues at sterile injectable facilities across the industry
• Early 2016: Sandoz discontinued its Cefepime injection product line, removing a significant source of supply from the market
• 2016–present: The brand-name product Maxipime (Pfizer) was also discontinued. The market transitioned entirely to generic production from manufacturers including Hospira/Pfizer, Baxter, B. Braun, Hikma, Apotex, Eurohealth, and Sagent
• 2023–2026: Continued intermittent shortages tracked by both the FDA Drug Shortage Database and ASHP. Supply availability has varied by formulation (premixed bags vs. powder vials) and dose strength (500 mg, 1 g, 2 g)

The ASHP Drug Shortage Detail page for Cefepime Injection remains an authoritative source for real-time manufacturer updates and estimated resupply dates.

Prescribing Implications

The ongoing shortage has several clinical implications that prescribers should consider:

Empiric Therapy Selection

When Cefepime is unavailable for empiric therapy — particularly for febrile neutropenia or hospital-acquired pneumonia — clinicians should review institutional antibiograms and local resistance patterns to select appropriate alternatives. The IDSA and ASCO guidelines for febrile neutropenia list Ceftazidime, Piperacillin-Tazobactam, and carbapenems (Meropenem, Imipenem-Cilastatin) as acceptable monotherapy options.

Dose Optimization

Extended infusion protocols (infusing Cefepime 2 g over 3–4 hours rather than the standard 30 minutes) have been studied and may optimize pharmacokinetic/pharmacodynamic (PK/PD) targets, particularly for organisms with higher MICs. This approach may allow institutions to achieve therapeutic goals while conserving supply.

Neurotoxicity Considerations

The FDA's 2012 Drug Safety Communication highlighted the risk of seizures and other neurotoxicity — including encephalopathy, myoclonus, and non-convulsive status epilepticus — in patients not receiving appropriate dose adjustments for renal impairment. When switching patients between antibiotics during a shortage, ensure that Cefepime dosing is recalculated based on current creatinine clearance. Patients aged 50 and older with renal dysfunction are at highest risk.

For detailed interaction information, see Cefepime Drug Interactions: What to Avoid.

Culture-Directed De-escalation

When Cefepime supply is limited, prioritize its use for culture-confirmed infections where Cefepime is the optimal agent (e.g., AmpC-producing Enterobacterales, susceptible Pseudomonas). De-escalate to narrower-spectrum agents when culture and sensitivity data allow.

Current Availability Picture

Supply availability fluctuates by manufacturer, formulation, and distribution channel. Key observations for 2026:

• Premixed IV bags (1 g/50 mL, 2 g/100 mL) may experience tighter supply than powder vials due to additional manufacturing complexity
• Powder vials (500 mg, 1 g, 2 g) from multiple generic manufacturers are generally more consistently available, though allocation limits may apply
• Regional variability: Some health systems and geographic regions may experience greater shortages depending on their primary distributor (McKesson, Cardinal Health, AmerisourceBergen/Cencora)
• Specialty and compounding pharmacies may have access to alternative supply channels for outpatient IV therapy patients

Providers can direct patients to Medfinder for Providers to check real-time Cefepime availability across pharmacies and infusion centers.

Cost and Access Considerations

For patients transitioning to outpatient parenteral antibiotic therapy (OPAT), cost and access become significant factors:

• Cash price: Generic Cefepime ranges from approximately $90 to $365 for a typical course (9 vials of 2 g) without insurance
• Discount programs: SingleCare and similar programs may reduce costs to $50–$93
• Insurance coverage: Most plans cover Cefepime as a preferred injectable antibiotic. Inpatient administration is typically included in facility charges. Outpatient IV therapy may require prior authorization under medical benefits (Part B for Medicare)
• Patient assistance: NeedyMeds, RxAssist, and hospital financial assistance programs can help uninsured or underinsured patients. Pfizer RxPathways may also offer support

For a patient-facing resource on cost savings, see How to Save Money on Cefepime.

Tools and Resources for Providers

Several resources can help clinicians manage Cefepime shortage situations:

• Medfinder for Providers: Real-time medication availability search across pharmacies and infusion centers. Share with patients who need help locating Cefepime for outpatient therapy
• ASHP Drug Shortage Resource Center: Manufacturer-specific updates, alternative therapy guidance, and conservation strategies
• FDA Drug Shortage Database: Official shortage status, manufacturer information, and estimated resolution timelines
• Institutional Antimicrobial Stewardship Programs: Most hospital stewardship teams develop shortage management protocols that include approved alternative agents, dose optimization strategies, and criteria for Cefepime use prioritization

Looking Ahead

The structural challenges driving sterile injectable shortages — limited manufacturers, thin margins, complex production requirements, and fragile supply chains — are unlikely to resolve quickly. The pharmaceutical industry and regulatory agencies are exploring measures to improve supply chain resilience, including:

• FDA incentives for manufacturers to maintain or increase production of shortage-prone drugs
• Quality management improvements at sterile injectable facilities
• Increased transparency in supply chain reporting
• Development of new combination products (e.g., Cefepime-Enmetazobactam/Exblifep) that may expand treatment options

In the meantime, proactive shortage management — including formulary planning, alternative therapy protocols, and patient communication — remains essential.

Final Thoughts

The Cefepime shortage is a systemic challenge that requires ongoing clinical vigilance and institutional planning. By staying informed about supply trends, optimizing prescribing practices, and leveraging tools like Medfinder for Providers, clinicians can continue to deliver effective care even when preferred agents are in short supply.

For a complementary guide on helping patients navigate availability, see How to Help Your Patients Find Cefepime in Stock.